Platelet-derived growth factor-b (PDGF-B) induced by hypoxia promotes the survival of pulmonary arterial endothelial cells through the PI3K/Akt/stat3 pathway

Cellular Physiology and Biochemistry

Volumn 35, Issue 2, 2015, Pages 441-451

  Li, Limin ^a   Xu, Mengyuan ^a   Li, Xiaoxia ^a   Lv, Chengfang ^a   Zhang, Xiaoqian ^a   Yu, Hongjuan ^a   Zhang, Mingwen ^a   Fu, Yueyue ^a   Meng, Hongbin ^a   Zhou, Jin ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Hypoxia; Platelet derived growth factor B; Pulmonary artery endothelial cells; Stat3

Indexed keywords

CASPASE 3; CASPASE 9; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR B; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SMALL INTERFERING RNA; STAT3 PROTEIN; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; 6,7-DIMETHOXY-3-PHENYLQUINOXALINE; BENZAMIDE DERIVATIVE; CHROMONE DERIVATIVE; IMATINIB; MORPHOLINE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TYRPHOSTIN;

ANIMAL CELL; APOPTOSIS; ARTERY ENDOTHELIUM; ARTICLE; CELL GROWTH; CELL HYPOXIA; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HYPOXIA; LUNG ARTERY; MITOCHONDRION; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PULMONARY ARTERIAL ENDOTHELIAL CELL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING; ANIMAL; BOVINE; CYTOLOGY; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PULMONARY ARTERY;

ANIMALS; APOPTOSIS; BENZAMIDES; CATTLE; CELL HYPOXIA; CELL SURVIVAL; CHROMONES; ENDOTHELIAL CELLS; MAP KINASE SIGNALING SYSTEM; MORPHOLINES; PHOSPHORYLATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-SIS; PULMONARY ARTERY; PYRIMIDINES; TYRPHOSTINS;

EID: 84921868557     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000369709     Document Type: Article

References (39)

1. Shao D1, Park JE, Wort SJ: The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. Pharmacol Res 2011; 63: 504-511.
2. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-54.
3. Haworth SG: Pulmonary endothelium in the perinatal period. Pharmacol Rep 2006; 58: S153-64.
4. Budhiraja R, TuDer RM, Hassoun PM: Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109: 159-165.
5. Celermajer DS, Cullen S, Deanfield JE: Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation 1993; 87: 440-446.
6. Oechslin E, Kiowski W, Schindler R, Bernheim A, Julius B, Brunner-La Rocca HP: Systemic endothelial dysfunction in adults with cyanotic congenital heart disease. Circulation 2005; 112: 1106-1112.
7. Mukai Y, Rikitake Y, Shiojima I, Wolfrum S, Satoh M, Takeshita K, Hiroi Y, Salomone S, Kim HH, Benjamin LE, Walsh K, Liao JK: Decreased vascular lesion formation in mice with inducible endothelial-specific expression of protein kinase Akt. J Clin Invest 2006; 116: 334-343.
8. Monick MM, Hunninghake GW: Activation of second messenger pathways in alveolar macrophages by endotoxin. Eur Respir J 2002; 20: 210-222.
9. Chow LQ, Eckhardt SG: Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007; 25: 884-896.
10. Faivre S, Demetri G, Sargent W, Raymond E: Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6: 734-745.
11. Darnell JE, Kerr IM, Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421.
12. Mertens C, Darnell JE: Snapshot: JAK-STAT signaling. Cell 2007; 131: 612.
13. Sehgal PB, Levy DE, Hirano T. (editors): Signal Transducers and Activators of Transcription (STATs): Activation and Biology. Dordrecht, The Netherlands: Kluwer Academic Press 2003, pp 1-746.
14. Sehgal PB: Plasma membrane rafts and chaperones in cytokine/STAT signaling. Acta Biochim Pol 2003; 50: 583-594.
15. Turkson J: STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 2004; 8: 409-422.
16. Myllarniemi M, CalDeron L, Lemstrom K, Buchdunger E, Hayry P: Inhibition of platelet-Derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation. FASEB J 1997; 11: 1119-1126.
17. Sano H, Sudo T, Yokode M, Murayama T, Kataoka H, Takakura N, Nishikawa S, Nishikawa SI, Kita T: Functional blockade of platelet-Derived growth factor receptor-beta but not of receptor-alpha prevents vascular smooth muscle cell accumulation in fibrous cap lesions in apolipoprotein E-deficient mice. Circulation 2001; 103: 2955-2960.
18. Seifert RA, Hart CE, Phillips PE, Forstrom JW, Ross R, Murray MJ, Bowen-Pope DF: Two different subunits associate to create isoform-specific platelet-Derived growth factor receptors. J Biol Chem 1989; 264: 8771-8778.
19. Kawai-Kowase K, Owens GK: Multiple repressor pathways contribute to phenotypic switching of vascular smooth muscle cells. Am J Physiol Cell Physiol 2007; 292: C59-C69.
20. Ogawa A, Nakamura K, Matsubara H, Fujio H, Ikeda T, Kobayashi K, Miyazaki I, Asanuma M, Miyaji K, Miura D, Kusano KF, Date H, Ohe T: Prednisolone inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. Circulation 2005; 112: 1806-1812.
21. Medhora M1, Chen Y, Gruenloh S, Harland D, Bodiga S, Zielonka J, Gebremedhin D, Gao Y, Falck JR, Anjaiah S, Jacobs ER: 20-HETE increases superoxide production and activates NAPDH oxidase in pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol 2008; 294: L902-911.
22. Wang Z, Tang X, Li Y, Leu C, Guo L, Zheng X, Zhu D: 20-Hydroxyeicosatetraenoic acid inhibits the apoptotic responses in pulmonary artery smooth muscle cells. Eur J Pharmacol 2008; 588: 9-17.
23. Ma J, Zhang L, Li S, Liu S, Ma C, Li W, Falck JR, Manthati VL, Reddy DS, Medhora M, Jacobs ER, Zhu D: 8, 9-Epoxyeicosatrienoic acid analog protects pulmonary artery smooth muscle cells from apoptosis via ROCK pathway. Exp Cell Res 2010; 316: 2340-2353.
24. Mao W, Iwai C, Liu J, Sheu SS, Fu M, Liang CS: Darbepoetin alfa exerts a cardioprotective effect in autoimmune cardiomyopathy via reduction of ER stress and activation of the PI3K/Akt and STAT3 pathways. J Mol Cell Cardiol 2008; 45: 250-260.
25. Zhang X, Shan P, Alam J, Fu XY, Lee PJ: Carbon monoxide differentially modulates STAT1 and STAT3 and inhibits apoptosis via a PI3K/Akt and p38 kinase dependent STAT3 pathway during anoxiareoxygenation injury. J Biol Chem 2005; 280: 8714-8721.
26. Ponnusamy M, Pang M, Annamaraju PK, Zhang Z, Gong R, Chin YE, Zhuang S: Transglutaminase-1 protects renal epithelial cells from hydrogen peroxide-induced apoptosis through activation of STAT3 and AKT signaling pathways. Am J Physiol Renal Physiol 2009; 297: F1361-70. 13
27. Farkas L, Gauldie J, Voelkel NF, Kolb M: Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors. Am J Respir Cell Mol Biol 2011; 45: 1-15.
28. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, Voelkel NF, TuDer RM: Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001; 15: 427-438.
29. Xu X, Zhang XA, Wang DW: The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Adv Drug Deliv Rev 2011; 63: 597-609.
30. Orlandi A, Francesconi A, Cocchia D, Corsini A, Spagnoli LG: Phenotypic heterogeneity influences apoptotic susceptibility to retinoic acid and cis-platinum of rat arterial smooth muscle cells in vitro: Implications for the evolution of experimental intimal thickening. Arterioscler Thromb Vasc Biol 2001; 21: 1118-1123.
31. Sarker D, Reid AH, Yap TA, de Bono JS: Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009; 15: 4799-805.
32. Huang S: Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res 2007; 13: 1362-1366.
33. Goswami A, Ranganathan P, Rangnekar VM: The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target. Cancer Res 2006; 66: 2889-2892.
34. Datta SR, Brunet A, Greenberg ME: Cellular survival: a play in three Akts. Genes 1999; 13: 2905-2927.
35. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD: Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001; 17: 615-675.
36. Luo J, Manning BD, Cantley LC: Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003; 4: 257-262.
37. Lei X, Chen Y, Du G, Yu W, Wang X, Qu H, Xia B, He H, Mao J, Zong W, Liao X, Mehrpour M, Hao X, Chen Q: Gossypol induces Bax/Bak-independent activation of apoptosis and cytochrome c release via a conformational change in Bcl-2. FASEB J 2006; 20: 2147-2149.
38. Ding J, Zhang Z, Roberts GJ, Falcone M, Miao Y, Shao Y, Zhang XC, Andrews DW, Lin J: Bcl-2 and Bax interact via the BH1-3 groove-BH3 motif interface and a novel interface involving the BH4 motif. J Biol Chem 2010; 285: 28749-2863.
39. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C: Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: Bax ratio. Cancer Res 2002; 62: 4592-4598.